Maternal Thyroid Function and Biochemical Markers of Placental Function in Early Pregnancy
- PMID: 39370704
- DOI: 10.1111/cen.15145
Maternal Thyroid Function and Biochemical Markers of Placental Function in Early Pregnancy
Abstract
Objective: A link between maternal thyroid function and the placental biomarkers, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF), has been brought forward. This study aimed to describe their association in early pregnancy.
Design: Retrospective cohort study.
Participants: Eight hundred and fifty-eight pregnant women from the North Denmark Region, 2013, with blood samples drawn in early pregnancy.
Measurements: Thyroid-stimulating hormone (TSH), free thyroxine (fT4), thyroid-peroxidase antibodies (TPO-Ab), thyroglobulin antibodies (Tg-Ab) (ADVIA Centaur XPT, Siemens Healthineers), sFlt-1 and PlGF (Kryptor Compact, ThermoFisher Scientific) were measured. The association between maternal TSH and fT4 and percentile (pc) levels of sFlt-1 and PlGF (< 25th pc, 25-75th pc, > 75th pc) was evaluated using regression analysis and reported as adjusted beta coefficient (aβ). The frequency of maternal thyroid autoantibodies (TPO-Ab > 60 U/mL or Tg-Ab > 33 U/mL) by pc levels of sFlt-1 and PlGF was compared using chi-squared test.
Results: Higher levels (> 75th pc) of sFlt-1 associated with lower TSH (aβ 0.62, 95% CI: 0.51-0.76) and higher fT4 (aβ 1.03, 95% CI: 1.01-1.05). Higher levels of PlGF associated with lower TSH (aβ 0.82, 95% CI: 0.69-0.98), but not with levels of fT4 (aβ 1.00, 95% CI: 0.97-1.02). No association with maternal thyroid autoantibodies was found (TPO-Ab: sFlt-1: p-value 0.5 and PlGF: p-value 0.1; Tg-Ab: sFlt-1: p-value 0.7 and PlGF: p-value 0.1).
Conclusions: In a large cohort of Danish pregnant women, higher levels of sFlt-1 and PlGF associated with maternal thyroid function in early pregnancy, while there was no association with maternal thyroid autoantibodies.
Keywords: PlGF; TSH; autoimmunity; gestation; sFlt‐1.
© 2024 John Wiley & Sons Ltd.
References
-
- E. K. Alexander, E. N. Pearce, G. A. Brent, et al., “2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum,” Thyroid 27 (2017): 315–389.
-
- U. Feldt‐Rasmussen, G. Effraimidis, S. Bliddal, and M. Klose, “Consequences of Undertreatment of Hypothyroidism,” Endocrine 84 (2023): 301–308.
-
- M. Colicchia, L. Campagnolo, E. Baldini, S. Ulisse, H. Valensise, and C. Moretti, “Molecular Basis of Thyrotropin and Thyroid Hormone Action During Implantation and Early Development,” Human Reproduction Update 20 (2014): 884–904.
-
- E. Bujold, S. Roberge, Y. Lacasse, et al., “Prevention of Preeclampsia and Intrauterine Growth Restriction With Aspirin Started in Early Pregnancy: A Meta‐Analysis,” Obstetrics & Gynecology 116 (2010): 402–414.
-
- H. Stepan, A. Galindo, M. Hund, et al., “Clinical Utility of sFlt‐1 and PlGF in Screening, Prediction, Diagnosis and Monitoring of Pre‐Eclampsia and Fetal Growth Restriction,” Ultrasound in Obstetrics & Gynecology 61 (2023): 168–180.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous